Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04798287 · ClinicalTrials.gov registry record
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 105,711
- Enrollment target
NCT04798287: Completed study, sponsored by Brigham and Women's Hospital.
NCT04798287 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 105,711 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04798287 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 105,711 participants
- Enrollment target
Study Summary
There are two main aims of this study. First aim is to compare the risk of composite cancer outcomes, between patients treated with tofacitinib and patients treated with TNF inhibitors (TNFi) for rheumatoid arthritis (RA) among, 1) "real world evidence (RWE)" cohorts including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohorts including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial. Second aim is to examine the risk of common solid cancers (lung, colorectal, breast, prostate), hematological cancers, and non-melanoma skin cancer as separated endpoints when comparing tofacitinib with TNFi in patients with RA among, 1) "real world evidence (RWE)" cohort including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohort including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.
Interventions
- DRUG Tofacitinib
- DRUG TNF Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105,711 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2022-05-16 |
What the finished NCT04798287 record still lists
NCT04798287 is an observational study that tracks outcomes without assigning an intervention. Its 105,711 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Tofacitinib is the first listed.
NCT04798287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04798287 about?
NCT04798287 is a clinical study titled "Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints". There are two main aims of this study. First aim is to compare the risk of composite cancer outcomes, between patients treated with tofacitinib and patients treated with TNF inhibitors (TNFi) for rheumatoid arthritis (RA) among, 1) "real world evidence (RWE)" cohorts including routine care patient ...
What is the current status of trial NCT04798287?
This trial is currently completed. The enrollment target is 105,711 participants. The study started on 2021-03-10. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04798287?
The interventions under investigation include: Tofacitinib (DRUG), TNF Inhibitor (DRUG).
Who is sponsoring clinical trial NCT04798287?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05804188 · 105,000 participants
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
- NCT02917460 · 102,000 participants · NA
Rady Children's Institute Genomic Biorepository
- NCT05741112 · 100,500 participants · NA
The Long COVID-19 Wearable Device Study
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI